Stephens assumed coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report published on Tuesday, MarketBeat.com reports. The firm issued an overweight rating and a $140.00 price objective on the biotechnology company’s stock. Other equities analysts have also issued research reports about the company. SVB Leerink raised Blueprint Medicines from an underperform […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 30th, there was short interest totalling 4,540,000 shares, a growth of 6.8% from the April 15th total of 4,250,000 shares. Based on an average daily volume of 830,500 shares, […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Free Report) was the recipient of a significant growth in short interest in April. As of April 30th, there was short interest totalling 4,540,000 shares, a growth of 6.8% from the April 15th total of 4,250,000 shares. Based on an average trading volume of 830,500 shares, the days-to-cover ratio […]
Blueprint Medicines (NASDAQ:BPMC) Upgraded to Market Perform by SVB Leerink tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.
The Goldman Sachs Group Increases Blueprint Medicines (NASDAQ:BPMC) Price Target to $168 00 dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.